Health Yuan products gain inclusion in national medical insurance catalog

Health Yuan Pharmaceutical Group Industry Co., Ltd. announced today that 218 of its products, including those from its subsidiaries, have been successfully included in the new "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog," effective January 1, 2026. This catalog update comprises 94 Class A and 124 Class B products.

Notable inclusions and updates feature injection products like Aripiprazole Microspheres, which secured entry through negotiation, and Triptorelin Acetate Microspheres, which gained an expanded indication. Additionally, Tobramycin Inhalation Solution and Esomeprazole Sodium Injection saw their existing entries successfully renewed.

The company stated that no products were delisted from the Medical Insurance Catalog. This inclusion is expected to expand market access and improve drug availability, projecting a positive impact on the company's future operating performance. However, Health Yuan cautions investors that future sales performance is subject to industry policy changes and market environment shifts.